Description:

North Central Cancer Treatment Group N0577 Event Monitoring Form Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C090D31-BB06-2FAA-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C090D31-BB06-2FAA-E044-0003BA3F9857

Keywords:
Versions (3) ▾
  1. 12/18/14
  2. 1/8/15
  3. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one pleaselog in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Event Monitoring Form N0577

No Instruction available.

  1. StudyEvent: North Central Cancer Treatment Group N0577 Event Monitoring Form
    1. No Instruction available.
Header
Are data amended (If yes, highlight amended areas)
Were you able to obtain any information about the patient since the last report (If this is the first event monitoring form check yes, enter assessment date and complete the rest of the form.)
Vital Status
Vital Status
Primary Cause of Death
Disease Follow-up Status
Has the patient had a documented clinical assessment for this cancer? (since submission of the last event monitoring form)
Notice Of First Relapse/progression In The Event Monitoring Phase
Has the patient developed a first relapse or progression that has not been previously reported
Site of relapse/progression (s)
Method of Evaluation
Notice Of First Subsequent Treatment
Has the patient received subsequent treatment for this cancer that has not been previously reported
Notice Of New Primary
Has a new primary cancer or MDS been diagnosed that has not been previously reported? (myelodyplastic syndrome)
Description Of Primary Disease
Has the patient experienced (prior to treatment for progression or relapse or a second primary, and prior to non-protocol treatment) any severe (grade >=3) long term toxicity that has not been previously reported?
CTC AE Attribution Code